AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease
Acquiring Company
AbbVie Inc.
Acquired Company
Landos Biopharma, Inc.
North ChicagoBlacksburgManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
AbbVie has successfully completed the acquisition of Landos Biopharma, Inc., adding the first-in-class investigational asset, NX-13, to its pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD). This strategic acquisition strengthens AbbVie's position in the field of immunology and demonstrates its commitment to developing innovative therapies for complex and critical conditions.
Quick answer
AbbVie Inc. is acquiring Landos Biopharma, Inc., announced May 23, 2024. AbbVie Inc. is based in North Chicago, Illinois, United States.
- Who acquired Landos Biopharma, Inc?
- AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on May 23, 2024.
- How much did AbbVie Inc. pay for Landos Biopharma, Inc?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Landos Biopharma, Inc. based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Landos Biopharma, Inc. is based in Blacksburg, Virginia, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- AbbVie completes acquisition of Celsius Therapeutics, Inc. to advance therapies for inflammatory disease (June 27, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products (July 2, 2024)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Landos Biopharma, Inc.?
Landos Biopharma, Inc. was acquired by AbbVie Inc., based in North Chicago. The deal was reported on May 23, 2024. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Landos Biopharma, Inc.?
AbbVie Inc.'s acquisition of Landos Biopharma, Inc. was reported on May 23, 2024. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Landos Biopharma, Inc. do?
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. It is privately held, operating in Biotechnology, and is based in Blacksburg.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.